FEBRUARY 06, 2014 / 1:30PM, SAN.PA - Full Year 2013 Sanofi SA Earnings Conference Call
`
`Africa and Middle East continue to contribute to the double-digit growth in emerging markets reporting EUR568m of sales in the fourth quarter.
`
`Finally, looking at Eastern Europe, Russia and Turkey, this region's growth of 5% was driven by sales mainly in Russia of EUR250m, up 10% and also
`by Turkey with sales growth of 16% for the quarter.
`
`If we go to slide number 22, we show really how Sanofi is poised to capture future growth in fast growing markets. Our scorecard in emerging
`markets summarizes key metrics of our leading position and how we will continue to leverage our existing presence in these regions.
`
`Moving from left to right, you can see that Sanofi is the undisputed number one healthcare company in emerging markets with a market share of
`5.7%. Our leadership position is well balanced between BRIC and non-BRIC countries. We have a broad and strong presence in these markets in
`terms of product portfolio, sales forces of over 23,000 people and a very wide network of 37 industrial sites. This really puts us in a unique position
`to capitalize on ongoing trends related to demographics, urbanization, expansion of the middle class, higher disposable incomes and consequently
`a strong increase in the demand for healthcare. As we continue to hone our execution strategy in fast-growing markets, we will maximize our
`growth opportunities in these regions in the years to come.
`
`So if we move to slide number 23, and we look at the other geographies, we can really see also improving sales trend throughout 2013 in the US
`representing 31% of sales, but also in Western Europe, making up 23% of sales. Specifically I want to highlight the performance in the fourth quarter
`where both in the US and Europe, we have returned to growth.
`
`So with that, I will turn over to Pascale to discuss diabetes and CHC business performance.
`
`Pascale Witz - Sanofi SA - EVP, Global Divisions & Strategic Commercial Development
`
`Thank you, Peter. So, let`s start with diabetes on slide 24 where we see the Lantus impressive performance showing yet another year of double-digit
`growth reaching sales of EUR5.7b in 2013. Lantus is clearly the first choice for insulin therapy.
`
`With over 8m patients worldwide, more than 10 years of clinical experience and extensive cardiovascular safety data, Lantus reported its 12th
`consecutive quarter of growth in Q4 2013 with sales up 20%. Part of this success is supported by the conversion over to the SoloSTAR pen which
`now represents 58% of the US sales and the majority of the sales in Europe. Our other innovative pen solutions contributed to the success of Lantus
`in other geographies.
`
`So turning on to Lyxumia on slide 25, we reiterate the key benefits of our once-daily prandial GLP-1 Lyxumia which complements basal insulin.
`Lyxumia has a pronounced postprandial glucose lowering effect and a limited risk of hypoglycemia. It can be used in combination with overall
`therapies and with basal insulin. It is now commercially available in several countries including Germany, UK, Spain, Japan and Mexico and we're
`encouraged by its initial market uptake. So as for the US, we continue to expect to resubmit our NDA to the FDA in 2015 after completion of the
`ELIXA cardiovascular outcome trial.
`
`Turning on to slide 26, where we look at another of our growth platforms with consumer healthcare. We are the third largest consumer healthcare
`player in a large but clearly fragmented OTC market. Q4 sales were up 6.1% reaching EUR722m. For the full year, total sales were EUR3b, up 5%
`driven by the growth in the US and in emerging markets.
`
`Our top seven brands today account for 40% of total sales. And very recently, we have been busy preparing for the launch of Nasacort OTC in the
`US, which occurred this week, right in time for the spring allergy season. Nasacort OTC 24 hours will be the first and only nasal spray in its class to
`be available without a prescription.
`
`With that, I will turn it over to Olivier Charmeil to review the vaccines business.
`
`THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us
`
`©2014 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited
`without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its
`affiliated companies.
`
`7
`
`Mylan Ex.1066
`Mylan v. Sanofi - IPR2018-01676
`
`